Company Profiles

driven by the PitchBook Platform

Edimer Pharmaceuticals

Edimer Pharmaceuticals
Out of Business LATEST DEAL TYPE

Developer of drugs for the treatment of X-linked hypohidrodic ectodermal dysplasia (XLHED) designed to deliver a significant and durable improvement in the health and quality of life for future generations affected by XLHED. The company's drug therapy treats a rare genetic condition that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems and hair and tooth malformations, enabling health care related people to treat XLHED.

Ownership Status
Out of Business
Financing Status
Formerly VC-Backed
Primary Industry
Drug Discovery
Primary Office
55 Cambridge Parkway
Suite 102W
Cambridge, MA 02142
United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Edimer Pharmaceuticals’s full profile, request a free trial.

Edimer Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jan-2017 0000 Completed Out of Business
3. Early Stage VC (Series B) 30-Jul-2013 0000 0000 000.00 Completed Startup
2. Grant 01-Nov-2010 $22M Completed Startup
1. Early Stage VC (Series A) 30-Jun-2009 $22M $22M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Edimer Pharmaceuticals Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned
Series B 00,000,000 00.000000 0.000 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 0.000 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Edimer Pharmaceuticals Executive Team (2)

Name Title Board
Neil Kirby Ph.D Chief Executive Officer, President & Board Member

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »
Questions or concerns about this profile? Reach out to